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A low fat oxidative capacity has been linked tomuscle diacylglycerol
(DAG) accumulation and insulin resistance. Alternatively, a low fat
oxidation rate may stimulate glucose oxidation, thereby enhancing
glucose disposal. Here, we investigated whether an ethyl-2-[6-(4-
chlorophenoxy)hexyl]-oxirane-2-carboxylate (etomoxir)-induced in-
hibition of fat oxidation leads to muscle fat storage and insulin
resistance. An intervention in healthy male subjects was combined
with studies in human primarymyotubes. Furthermore, muscle DAG
and triacylglycerol (TAG), mitochondrial function, and insulin sig-
naling were examined in etomoxir-treated C57bl6 mice. In humans,
etomoxir administration increased glucose oxidation at the expense
of fat oxidation. This effect was accompanied by an increased
abundance of GLUT4 at the sarcolemma and a lowering of plasma
glucose levels, indicative of improved glucose homeostasis. In mice,
etomoxir injections resulted in accumulation of muscle TAG and
DAG, yet improved insulin-stimulated GLUT4 translocation. Also in
human myotubes, insulin signaling was improved by etomoxir, in
the presence of increased intramyocellular lipid accumulation. These
insulin-sensitizing effects in mice and human myotubes were
accompanied by increased phosphorylation of AMP-activated pro-
tein kinase (AMPK). Our results show that a reduction in fat oxida-
tion leading to accumulation of muscle DAG does not necessarily
lead to insulin resistance, as the reduction in fat oxidation may
activate AMPK.
Obesity is a serious metabolic disorder characterized by ex-cessive fatty acid (FA) accumulation, giving rise to many
obesity-related complications including insulin resistance and
type 2 diabetes (1, 2). Skeletal muscle plays an important role in
the pathophysiology of this disease because it is responsible for
the majority of basal and insulin-stimulated glucose uptake (3, 4).
Randle et al. (5) postulated more than 40 y ago that increased FA
oxidation, resulting from high circulating free fatty acid (FFA)
levels, would impair insulin-stimulated muscle glucose utilization.
In this model, the availability of lipids as a fuel source impairs the
use of glucose as a substrate through inhibition of key glycolytic
enzymes. In fact, strategies to limit fat oxidation have been used
for diabetes treatment. For example, inhibitors of carnitine pal-
mitoyl transferase 1 (CPT1) like ethyl-2-[6-(4-chlorophenoxy)
hexyl]-oxirane-2-carboxylate (etomoxir) have initially been shown
to effectively lower blood glucose levels in diabetic patients (6, 7).
Similarly, short-term treatment of diabetic rats with etomoxir
resulted in favorable changes in fasting plasma glucose, FFA, and
triacylglycerol (TAG) concentrations (8, 9).
In contrast to these findings and to the Randle hypothesis,
studies from the last two decades revealed that the development
of muscle insulin resistance associates with a decreased rather
than increased fat oxidative capacity (10). Indeed, numerous
studies have shown that type 2 diabetes patients display
a diminished oxidative capacity (11, 12). A reduction in (fat)
oxidative capacity has been proposed to be responsible for ac-
cumulation of fat and FA intermediates in skeletal muscle. Es-
pecially the accumulation of diacylglycerol (DAG) has been
causally linked to the development of muscle insulin resistance
via an inhibitory effect on insulin signaling (13, 14). Likewise,
type 2 diabetes patients are characterized by elevated muscle
lipid content and a low mitochondrial capacity (15, 16). In that
sense, inhibiting fat oxidation may specifically have negative
effects on insulin-stimulated glucose metabolism and hence not
be an ideal strategy to improve insulin sensitivity. In this study we
examined the hypothesis that blocking fat oxidation by inhibiting
CPT1 pharmacologically with etomoxir (17, 18) has beneficial
effects on muscle glucose handling in non–insulin-stimulated
conditions, but would impair insulin signaling due to the accu-
mulation of intramyocellular lipids. To this end, we analyzed
muscle biopsies of a human study and performed additional
experiments in vitro using primary human myotubes and in vivo
using mice to examine the underlying mechanisms in more de-
tail. The human data revealed that in non–insulin-stimulated
conditions after etomoxir administration, glucose oxidation is
increased at the expense of fat oxidation. Interestingly, this was
accompanied by increased membrane GLUT4 and lowered
plasma glucose levels. In mice, we show that blocking fat oxi-
dation indeed leads to the accumulation of muscle DAG and
TAG. Surprisingly, this does not impede insulin signaling. Our
data in mice and in human primary myotubes revealed that these
effects are most likely attributed to activation of AMPK. Jointly,
these results suggest that the relationship between fat oxidation,
DAG accumulation, and insulin sensitivity is less straightforward
than has been previously proposed.
Results
Etomoxir Treatment of Humans. As reported previously (19), eto-
moxir treatment did not affect 24-h energy expenditure (11.01 ±
0.25 vs. 10.90 ± 0.41 MJ/24 h in etomoxir vs. placebo, P > 0.05),
but reduced 24-h fat oxidation and increased 24-h glucose oxi-
dation compared with placebo in humans (P < 0.05, Fig. 1A).
Fasting plasma TAG levels were reduced after etomoxir (416.4 ±
96.5 vs. 733.3 ± 131.6 μmol/L in etomoxir vs. placebo), and no
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treatment effects were observed in plasma FFA and glycerol
concentrations (FFA: 487.4 ± 75.6 vs. 381.5 ± 44.1 μmol/L in
etomoxir vs. placebo, P > 0.05 and glycerol: 88.7 ± 10.7 vs. 100.8 ±
25.2 μmol/L in etomoxir vs. placebo, P > 0.05). Measurement of
the homeostasis model assessment (HOMA) index revealed that
etomoxir treatment improved insulin sensitivity (P < 0.05, Fig.
1B), mainly due to lower fasting plasma glucose concentration,
(4.60 ± 0.14 vs. 4.85 ± 0.13 mmol/L in etomoxir vs. placebo, P <
0.05), with nonsignificant differences in fasting insulin concen-
trations (5.5 ± 0.4 vs. 6.7 ± 0.8 microunits/mL in etomoxir vs.
placebo, P > 0.05). Subjects also performed a 2-h cycling pro-
tocol at 50% of their maximal workload. During exercise, fat
oxidation was reduced (P < 0.05, Fig. 1C), blood glucose levels
markedly decreased (P < 0.05, Fig. 1D), and plasma lactate
levels increased at the end of exercise (2.71 ± 0.36 vs. 2.02 ±
0.28 in etomoxir vs. placebo, P < 0.05), suggesting reduced
reliance on fat as a substrate. Given that etomoxir affected
fasting plasma glucose levels and increased 24-h glucose oxi-
dation, we analyzed human muscle biopsies for the abundance
of GLUT4 in the membrane and sarcoplasm. Etomoxir ad-
ministration significantly increased the relative fraction of
GLUT4 associated with the membrane by 50% compared with
placebo (Fig. 1E). This effect was observed both in type 1 and
type 2 muscle fibers, although it tended to be more pronounced
in type 1 fibers (Fig. 1E). The relative fraction of GLUT4 near
the membrane tended to correlate with 24-h glucose oxidation
(r = +0.77, P = 0.07) and correlated strongly with 24-h glucose
balance (r = −0.94, P < 0.005).
Skeletal Muscle Mitochondrial Metabolism in Mice upon Etomoxir
Administration. The underlying mechanism by which etomoxir
might affect glucose homeostasis could not be further investigated
in human muscle biopsies, due to limited material. Therefore, we
used mice to investigate whether etomoxir treatment indeed re-
duced the entry of FAs into the mitochondria. Etomoxir treatment
did not affect food intake or body weight gain (Fig. S1). Mice were
killed after 8 d of etomoxir treatment. Separate addition of pal-
mitoyl-CoA and carnitine, thus requiring CPT1, resulted in a
significantly decreased state-3 mitochondrial respiration in mi-
tochondria isolated from muscle of etomoxir-treated mice (P <
0.05, Fig. 2A). Similarly, maximal respiratory capacity upon ad-
dition of the chemical uncoupler trifluorocarbonylcyanide phe-
nylhydrazone (FCCP) was significantly lower in the etomoxir-
compared with the placebo-treated animals (P < 0.05, Fig. 2A).
To investigate whether the effect of etomoxir treatment on
inhibiting fat oxidation was solely due to inhibition of CPT1 and
not a reduced overall mitochondrial function because of lip-
otoxicity, we further investigated mitochondrial function with
palmitoyl-carnitine (which does not require CPT1) and pyruvate
as substrates. Remarkably, both state-3 respiration and maximal
mitochondrial respiratory capacity with palmitoyl-carnitine as
a substrate were significantly elevated upon etomoxir treatment
compared with placebo (P < 0.05, Fig. 2B). When using pyruvate
as a substrate, both state-3 respiration and the maximal re-
spiratory capacity of the isolated mitochondria were not affected
by etomoxir treatment (P > 0.05, Fig. 2C). No differences in
β-hydroxyacyl-CoA dehydrogenase (β-HAD) activity were
detected between etomoxir and placebo groups (41.49 ± 6.00 vs.
45.17 ± 10.31 units/g protein, P > 0.05 in etomoxir vs. placebo),
indicating similar β-oxidative capacity. Western blotting of the
oxidative phosphorylation (OXPHOS) complexes revealed no
differences in expression of total OXPHOS levels [30.06 ± 10.05
vs. 31.48 ± 8.69 arbitrary units (AU), P > 0.05 in etomoxir
vs. placebo].
Intramyocellular Lipid Content in Mice upon Etomoxir Administration.
Quantification of intramyocellular lipid storage in mouse tibialis
anterior muscle revealed that etomoxir treatment resulted in a
3.6-fold higher intramyocellular lipid content (P= 0.06, Fig. 3A),
consistent with an inhibitory effect of etomoxir on fat oxidation.
Furthermore, etomoxir treatment resulted in a 5.9-fold increase
in skeletal muscle total DAG content (P < 0.05, Fig. 3B), which
was mainly accounted for by increases in poly- and mono-
unsaturated FAs in the DAG fraction [saturated (SAT): P =
0.059, monounsaturated fatty acid (MUFA): P < 0.05, and
polyunsaturated fatty acid (PUFA): P < 0.05]. Consistent with
Fig. 1. The effect of etomoxir in healthy males on (A) Twenty-four hour glucose, fat, and protein oxidation rates (modified from ref. 33). (B) HOMA index. (C)
Fat oxidation during a 2-h cycling protocol, represented as rates (Left) and area under the curve (in percentage, Right). (D) Blood glucose values during a 2-h
cycling protocol. (E) Relative fraction of total GLUT4 associated with the sarcolemma and separated for type 1 and 2 muscle fibers. Data are expressed as mean +
SEM (n = 10). *P < 0.05 etomoxir vs. placebo.






































the increase in muscle fat content, the protein expression of
perilipin 2 (PLIN2) and perilipin 5 (PLIN5), two lipid droplet
coating proteins suggested to be involved in lipid droplet me-
tabolism, were also induced by etomoxir treatment (P < 0.05,
Fig. 3 C and D).
Muscle Insulin Signaling upon Etomoxir Administration. Given the
increase in muscle TAG and DAG, we next investigated whether
the etomoxir-induced intramyocellular lipid accumulation im-
peded glucose homeostasis in mice. I.p. glucose tolerance tests
revealed that both basal and early postprandial plasma glucose
levels were markedly reduced in etomoxir-treated mice, with
a less pronounced increase in blood glucose levels upon glucose
injection (Fig. 4A). Next, we determined the effect of etomoxir
treatment on skeletal muscle insulin signaling by injecting a bolus
of insulin 10 min before killing the animals. Interestingly, despite
the pronounced accumulation of intramyocellular lipids, IRS1
serine phosphorylation on residue 307, a marker of muscle in-
sulin resistance, was decreased rather than increased with the
etomoxir treatment upon in vivo insulin stimulation (P < 0.05,
Fig. 4B). PKCθ protein content in the membrane, a direct
measurement of DAG-induced insulin resistance, was not in-
creased by etomoxir treatment (0.89 ± 0.16 vs. 1.13 ± 0.17 AU,
P > 0.05 in etomoxir vs. placebo). Furthermore, phosphorylation
of Akt, a downstream target of IRS, was increased rather than
decreased by etomoxir treatment (P < 0.05, Fig. 4C). In line with
this finding, insulin-stimulated GLUT4 translocation was also
increased in the etomoxir group compared with placebo (P <
0.05, Fig. 4D), indicating that insulin signaling was improved by
etomoxir, even in the face of elevated DAG levels. We next in-
vestigated whether the improvements in glucose homeostasis in
the etomoxir-treated animals, might be attributed to increased
AMPK activation. Indeed, phosphorylation of AMPK on Thr172
was increased upon etomoxir treatment (P < 0.05, Fig. 4E).
Taken together, these results suggest that inhibition of fat ox-
idation, by blocking mitochondrial entry of fatty acids, does not
necessarily lead to muscle insulin resistance. Rather, despite ac-
cumulation of fat in skeletal muscle, it may even increase muscle
insulin sensitivity via a mechanism that possibly involves the ac-
tivation of AMPK. To investigate whether similar effects can be
Fig. 2. Effect of etomoxir on the respiratory rates of freshly isolated skeletal musclemitochondria using a two-chamber oxygraph.Mitochondriawere incubated
in a respiration media containing malate. State-3 respiration (upon substrates and ADP) was achieved by addition of (A) palmitoyl CoA + carnitine, (B) palmitoyl-
carnitine, and (C) pyruvate as different substrates. Maximal oxygen flux (state U) was obtained by titration of the chemical uncoupler FCCP in the presence of
oligomycin. Values are expressed in nmol/mg mitochondrial protein/min (mean + SEM) (placebo n = 6, etomoxir n = 5). *P < 0.05 etomoxir vs. placebo.
Fig. 3. Effect of etomoxir in mice on (A) IMCL levels and (B) total DAG levels in tibialis anterior muscle and saturated (SAT), monounsaturated (MUFA), and
polyunsaturated (PUFA) fractions. Western blotting of the lipid droplet coating proteins (C) PLIN2 and (D) PLIN5 in tibialis anterior muscle of etomoxir-treated
mice. Data are expressed as mean + SEM (placebo n = 6, etomoxir n = 5). *P < 0.05 etomoxir vs. placebo.













































observed in humans, we treated human primary myotubes with
etomoxir. First, we confirmed that etomoxir treatment promotes
intramyocellular lipid accumulation (Fig. 4F). Regardless of the
pronounced fat accumulation, insulin-stimulated Akt phosphor-
ylation was not impaired by etomoxir treatment (Fig. 4G), and
etomoxir led to phosphorylation of AMPK on Thr172 after 3 h of
incubation (Fig. 4H).
Discussion
High-fat availability plays a prominent role in the onset of
skeletal muscle insulin resistance. Whereas Randle was the first
to postulate that elevated fat oxidation causes reduced insulin-
stimulated glucose uptake and thereby impedes insulin sensitiv-
ity, over the years more and more researchers discounted this
simple model of such a reciprocal regulation of FA oxidation and
glucose disposal. Rather, the idea evolved that a low FA oxida-
tive capacity is causally related to the development of insulin
resistance, via the accumulation of FA intermediates, which in-
terfere at several distinct steps in the insulin signaling cascade.
For example, acute elevation of circulating lipids leads to the
accumulation of DAG in muscle and thereby impairs insulin
action (20). We here show that blocking the entry of FAs into the
mitochondria by etomoxir increased glucose uptake and oxida-
tion at the expense of fat oxidation; both in non–insulin-stimu-
lated as well as insulin-stimulated conditions. Interestingly, the
accumulation of muscle TAG and DAG, as a result of etomoxir
administration, did not negatively affect muscle insulin signaling.
Here, we show that blocking fat oxidation by etomoxir in
healthy male subjects on a high-fat diet, clearly improved 24-h
glucose oxidation in the non–insulin-stimulated state at the ex-
pense of a lower fat oxidation. HOMA index suggests improved
insulin sensitivity upon etomoxir, which was mainly due to lower
plasma glucose values. Our results confirm previous human and
animal studies showing improved glucose oxidation and de-
creased blood glucose concentrations upon etomoxir adminis-
tration in the non–insulin-stimulated state (6–9). Consistent with
improved glucose oxidation, etomoxir interestingly induced an
increase in the sarcolemmal GLUT4 fraction in the non–insulin-
stimulated state. This increase is remarkable as GLUT4 trans-
location is considered to occur upon muscle contraction and/or
insulin stimulation. This finding suggests that inhibition of FA
oxidation at the level of CPT1 does not only increase glucose
oxidation through substrate competition at the TCA cycle, but
also induces a signal leading to GLUT4 translocation. Our ob-
servation that GLUT4 translocation was more pronounced in
type 1 compared with type 2 muscle fibers is consistent with the
suggestion that etomoxir-induced CPT1 inhibition (which is be-
lieved to be more manifest in type 1 muscle fibers) induces
a signal mediating GLUT4 translocation. Our data point toward
activation of AMPK as a possible signal that facilitated the
etomoxir-induced GLUT4 translocation. This notion is sup-
ported by our findings in human primary myotubes and in mice
that inhibition of fat oxidation by blocking mitochondrial entry of
FAs indeed activates AMPK. This activation of AMPK may be
directly due to either reduced fat oxidation or disturbances of
myocellular energy or glucose homeostasis, as reviewed before
(21, 22). However, this finding extends previous findings showing
that a reduction in fat oxidation, via the genetic manipulation of
malonyl-CoA dehydrogenase (MCD), leads to an improvement
in glucose homeostasis. In these studies, either AMPK was not
measured (23) or was unaffected (24). Why AMPK was not ac-
tivated in these previous studies cannot be deduced from the
present results, but together these studies do show that a mild
reduction in mitochondrial fatty acid entry promotes glucose
homeostasis.
In the last two decades, the prevailing model to explain the
development of skeletal muscle insulin resistance suggests that
the accumulation of FA intermediates in muscle—due to an
imbalance between fat oxidation and FA availability—inhibits
insulin signaling, thereby leading to reduced insulin-stimulated
GLUT4 translocation. We therefore also tested whether an
etomoxir-induced reduction in fat oxidation would increase
muscle lipid intermediates and impair insulin signaling in mice.
We confirmed that etomoxir administration solely affected CPT1
Fig. 4. Effect of etomoxir on (A) whole-body glucose tolerance measured by an ipGTT (2 g/kg bw glucose) in mice. Effect of etomoxir on the expression of
several proteins in the insulin signaling cascade was investigated in tibialis anterior muscle of mice. Western blotting of (B) pIRS1 (Ser307), (C) pAkt, and (D)
GLUT4. (E) Phosphorylation of AMPK was examined by Western blotting in mouse tibialis anterior muscle. Human myotubes were incubated with 100 μM
etomoxir and (F) IMCL accumulation is shown after 0, 3, and 6 h of etomoxir incubation. (G) Western blotting of pAkt in human myotubes incubated with
etomoxir for 0, 3, and 6 h in the absence or presence of insulin. (H) pAMPK protein expression upon 0, 3, and 6 h of etomoxir incubation in human myotubes,
measured by Western blotting. Representative Western blots are shown in Fig. S2. Data are expressed as mean + SEM (n = 10 per group for mice experiments,
n = 6–8 per group for cell experiments) *P < 0.05 etomoxir vs. placebo.






































and not overall mitochondrial function as respiration of a FA
substrate coupled to carnitine, thus bypassing CPT1, did not
decrease but even increased the respiration rates. The decreased
fat oxidation in etomoxir-treated animals was paralleled with
increased storage of muscle lipid intermediates. Both muscle
TAG and DAG levels were increased after etomoxir treatment,
and also PLIN2 and PLIN5, lipid droplet coating proteins in-
volved in lipid droplet metabolism, were increased by etomoxir
treatment. Remarkably however, whole body glucose tolerance
and muscle-specific insulin signaling were not negatively affected
in the etomoxir-treated mice compared with the control group.
Thus, insulin-stimulated GLUT4 translocation, as well as Akt
phosphorylation were increased upon etomoxir treatment. In
general, in conditions of lipid-induced insulin resistance both
the insulin receptor as well as IRS1 are negatively regulated
by serine phosphorylation, which opposes phosphorylation on
tyrosine residues, and thus impedes activation of downstream
targets, including Akt and GLUT4 (25). However, the insulin
signaling cascade was not hampered by serine 307 phosphory-
lation of IRS1, or increased presence of PKCθ at the membrane,
despite elevated DAG levels. We did confirm these findings in
human primary myotubes by showing that a marked increase in
intramyocellular lipid accumulation upon etomoxir treatment
did not negatively affect insulin signaling.
Although there are studies describing that activation of
AMPK can antagonize insulin action in muscle (26, 27), in other
cases, the insulin and AMPK signaling pathways work in the
same direction, particularly in processes that regulate plasma
glucose levels (28). Thus, it has been shown that Akt and Akt
substrate of 160 kDa (AS160) are important downstream sub-
strates involved in AMPK-mediated glucose uptake (29), and
AMPK activation could thereby overcome fat-induced insulin
resistance. However, in our study not only Akt phosphorylation
was increased after etomoxir treatment of primary human
myotubes and mice, but also the upstream activator of Akt, IRS1
serine 307 phosphorylation, was decreased in etomoxir-treated
mice. In that respect, Jakobsen et al. (30) reported a direct in-
teraction between AMPK and the most upstream component of
the insulin signaling cascade, IRS1, in mouse C2C12 myotubes
preincubated with 5-amino-1-beta-D-ribofuranosyl-imidazole-4-
carboxamide (AICAR), which correlated with a 65% increase in
insulin-stimulated IRS1-associated PI3 kinase activity. It could
therefore be postulated that the increased AMPK phosphoryla-
tion that we observed upon etomoxir treatment might contribute
to the improved insulin-stimulated insulin signaling.
As explained above, even though it seems possible that the
insulin signaling and AMPK pathway can work synergistically in
improving muscle glucose uptake, it is still remarkable that the
increased accumulation of lipid intermediates in muscle upon
etomoxir did not negatively impact insulin signaling substrates.
Elevated levels of the lipotoxic derivate DAG are generally
considered to cause lipid-induced insulin resistance (13). How-
ever, we previously reported that elevated muscle DAG levels
are not per se accompanied by skeletal muscle insulin resistance.
That is, we showed that myocellular DGAT1 overexpression, an
enzyme responsible for the conversion of DAG into inert TAG,
improved skeletal muscle insulin sensitivity, yet increased muscle
DAG levels (31). This phenomenon of improved insulin sensi-
tivity coupled to increased storage of DAG in muscle was also
reported in endurance-trained athletes (32). These findings in-
dicate that the role of the individual lipid intermediates in
causing muscle lipid-induced insulin resistance is not straight-
forward and seems to depend on several aspects, including cel-
lular energy status and the balance between lipid availability and
oxidation. Overall, our data suggest that blockade of fat oxida-
tion at the level of CPT1 by administration of etomoxir results in
improved insulin sensitivity through increased GLUT4-induced
glucose uptake both in non–insulin- as well as insulin-stimulated
conditions. Our results show that a reduction in fat oxidation
leading to the accumulation of muscle DAG and TAG levels
does not necessarily lead to muscle insulin resistance, probably
due to activation of AMPK.
Materials and Methods
Human Subjects. Healthy, lean young men [age 26.7 ± 2.8 y, body mass index
(BMI) 21.8 ± 0.4 kg/m2, n = 10] participated in the study. The medical ethics
committee of Maastricht University approved the study, and subjects gave
their written informed consent. Each subject underwent two treatments in
randomized order, as described previously (33). A detailed description of the
study design can be found in SI Materials and Methods.
Blood Analyses. Plasma nonesterified FAs, glycerol, glucose, and lactate were
measured with enzymatic assays automated on a Cobas Fara/Mira. Insulin con-
centration was determined using a radioimmunoassay (RIA) (Linco Research).
Muscle Biopsy and Analysis. Muscle biopsies were taken from the midthigh
region from Musculus vastus lateralis according to the Bergström technique
(34), freed from blood and any visible connective and adipose tissue, em-
bedded in Tissue-Tek (Tissue-Tek), and directly frozen in melting isopentane.
Immunofluorescence Assay. Fresh cryosections (5 μm) from human biopsies
were stained for simultaneous identification of fiber type and subcellular
GLUT4 content. Triple immunofluorescence was performed to discriminate
between type 1 and 2 fibers, simultaneously with the basement membrane
protein laminin to identify the sarcolemma and GLUT4 (35, 36).
Animals. Thirty-one14-wk-oldmaleC57BL6micewerehoused individually inan
environmentally controlled laboratory (temperature 22 ± 1 °C, relative hu-
midity 55 ± 2%, 12:12 h light-dark cycle). Mice were allowed ad libitum access
to a 45% high-fat diet (D01060502; Research Diets) for a period of 14 d.
On day 6 of the diet intervention, mice were randomly divided into two
groups (n = 15 for etomoxir and n = 16 for placebo). One group received
a daily i.p. injection of the CPT1 inhibitor, etomoxir [20 mg/kg body weight
(bw) dissolved in 0.9% NaCl (wt/vol); purchased from Sigma-Aldrich] during
the remaining 8 d of the diet intervention. The control group received a daily
i.p. injection of an equivalent volume of 0.9% (wt/vol) NaCl. On day 14, 10
animals of the etomoxir group and placebo group were subjected to an i.p.
glucose tolerance test. A bolus of 2 g/kg bw of glucose was injected after a 6-
h fast and blood was collected before (t = 0) and 15, 30, 60, and 120 min after
the bolus. On day 15, 10 mice of the placebo and etomoxir group received an
i.p. injection of insulin (10 units/kg) 10 min before killing. All mice were
anesthetized by a mixture of 79% (vol/vol) of CO2 and 21% (vol/vol) of O2,
followed by cervical dislocation. Anterior tibialis muscle from both hindlimbs
was rapidly dissected, frozen in liquid nitrogen-cooled isopentane, and stored
at −80 °C until further analyses. The remaining 5 animals in the etomoxir
group and the 6 remaining animals in the placebo group were killed without
an insulin bolus. Part of the muscles of these animals were used for mito-
chondrial respiration, the other part was used for intramyocellular lipid
content (IMCL) and DAG determination. All experiments were approved by
the institutional animal care and use committee of the Maastricht University
and complied with the principles of laboratory animal care.
Cell Culture Experiments. Samples of M. vastus lateralis from five healthy,
sedentary nondiabetic male subjects (age 52.6 ± 2.8 y, n = 5) were obtained by
muscle biopsy using the Bergström technique (34) and cultured as described
before (37). Differentiated myotubes were treated with 100 μM etomoxir
(Sigma) for 0, 3, and 6 h in the presence of 30 μM oleate conjugated to es-
sential fatty acid free BSA (ratio BSA:palmitate 1:2.5). Cells were harvested
posttreatment and lysed in Nonidet P-40 lysis buffer [62.5 mM Tris-HCL, 2%
(vol/vol) Nonidet P-40, 1.25 mM EDTA, protease and phosphatase inhibitors].
Intramyocellular Lipid Content. Cryosections (5 μm) from the midbelly region
of the tibialis anterior muscle of mice were stained for neutral lipids with Oil
Red O staining as described previously (36). Intramyocellular lipid content
was expressed per cell surface area. Fully differentiated myotubes were
fixed with 3.7% (vol/vol) formaldehyde in PBS for 20 min. Thereafter, slides
were incubated in 0.3% (wt/vol) Oil Red O in 60% (vol/vol) triethylphosphate
for 30 min. Subsequently, slides were mounted using mowiol. DAPI was in-
cluded with the mowiol to allow visualization of nuclei. Slides were exam-
ined using a Nikon E800 fluorescence microscope (Uvikon). Digital images
were captured and processed using Lucia G/F 5.49 image analysis software
(Nikon).













































DAG Measurement. Total lipids were extracted from frozen mouse tibialis
anterior muscle and DAG content was determined as described previously (31).
Mitochondrial Isolation and Oxygen Consumption. Isolation and oxygen con-
sumption measurements of mouse skeletal muscle mitochondria were per-
formed using a two-chamber oxygraph (Oroboros Instruments), as described
previously (38). Briefly, mitochondria were incubated in respiration medium
containing (100 mM sucrose, 20 mM K+-TES (PH 7.2), 50 mM KCl, 2 mM
MgCl2, 1 mM EDTA, 4 mM KH2PO4, 3 mM malate, and 0.1% of fatty acid free
BSA). Pyruvate (5 mM) was added as a carbohydrate-derived substrate.
Palmitoyl-carnitine (50 μM) and palmitoyl-CoA (50 μM) + carnitine (2 μM)
were used as fatty acid substrates, with the latter being CPT1 dependent.
After addition of substrates, ADP (450 mM) was added to initiate state-3
respiration, followed by oligomycin (1 mg/mL) to block ATP synthesis (state-4
respiration). Maximal oxygen flux (state uncoupled) was obtained by titra-
tion of the chemical uncoupler FCCP.
β-HAD Enzyme Activity. Activity of β-HAD, as a marker for β-oxidative capacity
was measured in tibialis anterior muscle homogenates of mice, as described
previously (39). Protein concentration was determined using a Bio-Rad
protein assay kit according to manufacturer instructions.
Western Blotting. The Western blots in mouse tibialis anterior muscle and
human myotubes were performed with antibodies against PLIN5 (GP31;
Progen), PLIN2 (GP41; Progen), OXPHOS (MS601; MitoSciences), Akt and pAkt
(Ser473) (9271 and 9272, respectively; Cell Signaling Technology, Bioké), pIRS
(Ser307) (2381S; Cell Signaling), PKCθ (2059; Cell Signaling), GLUT4 (sc-1608;
Santa Cruz, Bio-Connect), and AMPK and pAMPK (Thr172) (2532 and 2531,
respectively; Cell Signaling). Detailed information on the procedures can be
found in SI Materials and Methods.
Statistics. Data are presented as mean ± SEM. In the human trial, differences
between etomoxir and placebo were analyzed pairwise with Student t tests.
Pearsons correlation coefficients were calculated to determine the re-
lationship between selected variables. Differences between animal groups
were analyzed by a nonparametric t test. The i.p. glucose tolerance test was
analyzed by means of factorial repeated measures ANOVA to determine the
time, group, and time × group effect. For the human myotubes experiments,
the differences were determined by univariate ANOVA followed by Bon-
ferroni post hoc tests when applicable. For the analysis of pAkt in myotubes,
factorial ANOVA was used to determine the effect of incubation time and
insulin. The accepted level of statistical significance was P < 0.05 for all
analyses. All calculations were done using the Statistical Package for the
Social Sciences (SPSS 16.0 software).
ACKNOWLEDGMENTS. This study was funded by Top Institute (TI) Food and
Nutrition. TI Food and Nutrition, formerly known as Wageningen Center for
Food Sciences (WCFS), is a unique public/private partnership that generates
vision on scientific breakthroughs in food and nutrition, resulting in the
development of innovative products and technologies that respond to con-
sumer demands for safe, tasty, and healthy foods. Partners are major Dutch
food companies and research organizations. VICI Grant 918.96.618, VIDI
Grant 917.66.359, and VENI Grant 916.11.136 for innovative research from
the Netherlands Organization for Scientific Research supports the work of
P.S., M.K.C.H., and V.B.S.-H., respectively.
1. Boden G, Lebed B, Schatz M, Homko C, Lemieux S (2001) Effects of acute changes of
plasma free fatty acids on intramyocellular fat content and insulin resistance in
healthy subjects. Diabetes 50:1612–1617.
2. Bachmann OP, et al. (2001) Effects of intravenous and dietary lipid challenge on
intramyocellular lipid content and the relation with insulin sensitivity in humans.
Diabetes 50:2579–2584.
3. DeFronzo RA, et al. (1981) The effect of insulin on the disposal of intravenous glucose.
Results from indirect calorimetry and hepatic and femoral venous catheterization.
Diabetes 30:1000–1007.
4. Baron AD, Brechtel G, Wallace P, Edelman SV (1988) Rates and tissue sites of non-
insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255:
E769–E774.
5. Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its
role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet
1:785–789.
6. Hübinger A, Knode O, Susanto F, Reinauer H, Gries FA (1997) Effects of the carnitine-
acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and
substrate oxidation in NIDDM. Horm Metab Res 29:436–439.
7. Hübinger A, Weikert G, Wolf HP, Gries FA (1992) The effect of etomoxir on insulin
sensitivity in type 2 diabetic patients. Horm Metab Res 24:115–118.
8. Barnett M, Collier GR, O’Dea K (1992) The longitudinal effect of inhibiting fatty acid
oxidation in diabetic rats fed a high fat diet. Horm Metab Res 24:360–362.
9. Barnett M, Habito R, Cameron-Smith D, Yamamoto A, Collier GR (1996) The effect of
inhibiting fatty acid oxidation on basal glucose metabolism in Psammomys obesus.
Horm Metab Res 28:165–170.
10. Phielix E, Mensink M (2008) Type 2 diabetes mellitus and skeletal muscle metabolic
function. Physiol Behav 94:252–258.
11. Colberg SR, Simoneau JA, Thaete FL, Kelley DE (1995) Skeletal muscle utilization of
free fatty acids in women with visceral obesity. J Clin Invest 95:1846–1853.
12. Kelley DE, Simoneau JA (1994) Impaired free fatty acid utilization by skeletal muscle
in non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349–2356.
13. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171–176.
14. Timmers S, Schrauwen P, de Vogel J (2008) Muscular diacylglycerol metabolism and
insulin resistance. Physiol Behav 94:242–251.
15. Phielix E, et al. (2008) Lower intrinsic ADP-stimulated mitochondrial respiration un-
derlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients.
Diabetes 57:2943–2949.
16. Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in
human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950.
17. Declercq PE, et al. (1987) Characterization of the mitochondrial carnitine palmitoyl-
transferase enzyme system. I. Use of inhibitors. J Biol Chem 262:9812–9821.
18. Agius L, Meredith EJ, Sherratt HS (1991) Stereospecificity of the inhibition by eto-
moxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes. Biochem
Pharmacol 42:1717–1720.
19. Hinderling VB, Schrauwen P, LanghansW, Westerterp-PlantengaMS (2002) The effect
of etomoxir on 24-h substrate oxidation and satiety in humans. Am J Clin Nutr 76:
141–147.
20. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in
human muscle is associated with changes in diacylglycerol, protein kinase C, and
IkappaB-alpha. Diabetes 51:2005–2011.
21. Hardie DG (2011) Sensing of energy and nutrients by AMP-activated protein kinase.
Am J Clin Nutr 93:891S–896S.
22. Zhang BB, Zhou G, Li C (2009) AMPK: An emerging drug target for diabetes and the
metabolic syndrome. Cell Metab 9:407–416.
23. Koves TR, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation
contribute to skeletal muscle insulin resistance. Cell Metab 7:45–56.
24. Bouzakri K, et al. (2008) Malonyl CoenzymeA decarboxylase regulates lipid and glu-
cose metabolism in human skeletal muscle. Diabetes 57:1508–1516.
25. Zick Y (2004) Uncoupling insulin signalling by serine/threonine phosphorylation: A
molecular basis for insulin resistance. Biochem Soc Trans 32:812–816.
26. Gamble J, Lopaschuk GD (1997) Insulin inhibition of 5′ adenosine monophosphate-
activated protein kinase in the heart results in activation of acetyl coenzyme A car-
boxylase and inhibition of fatty acid oxidation. Metabolism 46:1270–1274.
27. Beauloye C, et al. (2001) Insulin antagonizes AMP-activated protein kinase activation
by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS
Lett 505:348–352.
28. Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and
insulin signaling. Circ Res 100:328–341.
29. Karlsson HK, et al. (2005) Insulin-stimulated phosphorylation of the Akt substrate
AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:
1692–1697.
30. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE (2001) 5′-AMP-activated protein
kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-
aminoimidazole-4-carboxamide riboside. J Biol Chem 276:46912–46916.
31. Timmers S, et al. (2011) Paradoxical increase in TAG and DAG content parallel the
insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle.
PLoS ONE 6:e14503.
32. Amati F, Dube JJ, Coen PM, Goodpaster BH (2009) Diacylglycerol and ceramide con-
tent in skeletal muscle insulin resistance: The next chapter in the story of good and
bad lipids? Obesity (Silver Spring) 17(Supplement 2):S71.
33. Schrauwen P, et al. (2002) Etomoxir-induced increase in UCP3 supports a role of un-
coupling protein 3 as a mitochondrial fatty acid anion exporter. FASEB J 16:
1688–1690.
34. Bergstrom J (1975) Percutaneous needle biopsy of skeletal muscle in physiological and
clinical research. Scand J Clin Lab Invest 35:609–616.
35. Borghouts LB, Schaart G, Hesselink MK, Keizer HA (2000) GLUT-4 expression is not
consistently higher in type-1 than in type-2 fibres of rat and human vastus lateralis
muscles; an immunohistochemical study. Pflugers Arch 441:351–358.
36. Koopman R, Schaart G, Hesselink MK (2001) Optimisation of oil red O staining permits
combination with immunofluorescence and automated quantification of lipids. His-
tochem Cell Biol 116:63–68.
37. Sparks LM, et al. (2011) Remodeling lipid metabolism and improving insulin re-
sponsiveness in human primary myotubes. PLoS ONE 6:e21068.
38. Nabben M, et al. (2008) The effect of UCP3 overexpression on mitochondrial ROS
production in skeletal muscle of young versus aged mice. FEBS Lett 582:4147–4152.
39. den Hoed M, Hesselink MK, van Kranenburg GP, Westerterp KR (2008) Habitual
physical activity in daily life correlates positively with markers for mitochondrial ca-
pacity. J Appl Physiol 105:561–568.
11716 | www.pnas.org/cgi/doi/10.1073/pnas.1206868109 Timmers et al.
D
ow
nl
oa
de
d 
at
 U
N
IV
E
R
S
IT
E
IT
 M
A
A
S
T
R
IC
H
T
 o
n 
S
ep
te
m
be
r 
28
, 2
02
1 
